Avelox and Pregnancy
It is currently unknown whether it is safe for pregnant women to take Avelox (moxifloxacin). Pregnancy problems could potentially occur, although the full risks of using the drug in pregnant humans are not known. In animal studies on Avelox and pregnancy, the medication increased the risk of fetal death, low fetal weight, and delayed bone development when high doses were given to pregnant rats.
Avelox® (moxifloxacin) is a prescription antibiotic. It may not be safe for use during pregnancy, although the full risks are not currently known. The manufacturer recommends that pregnant women take Avelox only if the potential benefits of the medication outweigh the possible risks to the fetus.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but that do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
When large doses of Avelox were given to pregnant rats, the medication did not cause birth defects. However, extremely large doses given to pregnant rats increased the risk of fetal death, low fetal weight, and slightly delayed bone development. In rabbits, the drug increased the risk of rib and vertebral defects. In monkeys, Avelox increased the risk of smaller fetuses. The medication has not been studied in pregnant women.
A pregnancy Category C medicine may be given to a pregnant woman if a healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child. If other, more suitable antibiotics are available (and are likely to be effective for treating a particular infection), Avelox should be avoided. However, if the medication appears to be necessary to treat an infection, the benefits may outweigh the potential risks.